Runway Growth Finance Corp. (RWAY) closed its definitive merger agreement with SWK Holdings Corporation (SWKH) on April 6 2026, paying a total of $249.0 million for the specialty‑finance company. The purchase price consists of $75.5 million in RWAY shares, valued at $11.93 per share, and $173.5 million in cash. The transaction brings SWK’s $218.6 million portfolio of finance receivables under RWAY’s ownership and adds a $30 million assumption of 9.00% senior notes due 2027.
The deal is expected to be accretive to RWAY’s net investment income and to boost the company’s healthcare and life‑science exposure from 14% at year‑end 2025 to roughly 32% of its portfolio. Pro‑forma assets after the transaction are projected to reach $1.2 billion, and the additional $9.0 million cash contribution from Runway Growth Capital LLC signals strong confidence in the combined platform’s resilience amid current macro conditions.
"We are pleased to announce the successful closing of our acquisition of SWK, which represents a meaningful step forward in advancing our ongoing portfolio optimization and diversification strategy. This transaction enhances our scale, deepens our investment capabilities in healthcare and life sciences, and further diversifies our portfolio," said David Spreng, Founder and CEO of Runway Growth Finance.
"Notably, our investment adviser committed an additional $9.0 million in cash as consideration to the stockholders of SWK, highlighting the team's confidence in the strength of our platform against the current macro backdrop, as well as its alignment with the BDC and its shareholders. Looking ahead, we believe we are well positioned to build on our diversified portfolio and capitalize on an improving opportunity set across verticals," Spreng added.
SWK’s financial performance prior to the acquisition was mixed. One source reported Q4 2025 revenue of $6.6 million with a basic EPS loss of $1.60, while another source indicated a Q4 2025 EPS of $1.41, exceeding expectations. The portfolio value at the time of the merger announcement was approximately $242 million, and the company’s portfolio of finance receivables was $218.6 million.
The acquisition positions RWAY to leverage SWK’s mid‑teen yield portfolio and specialized underwriting expertise in the sub‑$50 million life‑science financing niche, strengthening its competitive advantage in a high‑growth sector. With the combined entity’s expanded scale and diversified exposure, RWAY is better positioned to generate sustainable net investment income and to support future dividend coverage for its shareholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.